urrency, in a market with some constrained consumer spending. This reflects a quarter-on-quarter growth acceleration across all product categories and geographies.

Reflecting broad-based growth momentum and successful commercial execution over the first nine months of the year, International markets grew 13.2% and the U.S. 17.5% year-on-year at constant currency. Double-digit growth was achieved in both Injectable Aesthetics and Therapeutic Dermatology globally, as well as in the majority of Galderma’s top 10 markets. Galderma outperformed the market and gained share across both sub-segments of Injectable Aesthetics in both geographies, as well as in International markets for Dermatological Skincare. In Therapeutic Dermatology, Nemluvio continued its strong launch momentum in the U.S. and Germany, while rolling out several launches in International markets, with total net sales of 263 million USD.

Injectable Aesthetics

Injectable Aesthetics net sales
=*=*=*=*=*=
当前为第4/31页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页